Literature DB >> 16227803

K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients.

Ravindra K Gupta1, Ian L Chrystie, Siobhan O'Shea, Jane E Mullen, Ranjababu Kulasegaram, Cheuk Y W Tong.   

Abstract

The vast majority of HIV-1 infections globally are caused by subtype A or C, although little is known about their drug resistance profiles. We found that HAART-experienced patients infected with subtype A had a lower prevalence of K65R and Y181C than those with subtypes B or C, despite similar exposure to antiretroviral agents that select for these mutations. If confirmed, this information may be important in the planning of antiretroviral regimens in patients infected with HIV-1 subtype A.

Entities:  

Mesh：

Year:  2005        PMID： 16227803     DOI： 10.1097/01.aids.0000189860.36688.e5

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  14 in total

1.  Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

2.  HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

Authors:  K Theys; J Vercauteren; J Snoeck; M Zazzi; R J Camacho; C Torti; E Schülter; B Clotet; A Sönnerborg; A De Luca; Z Grossman; D Struck; A-M Vandamme; A B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

3.  The HIV-1 epidemic: low- to middle-income countries.

Authors:  Yiming Shao; Carolyn Williamson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

4.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

Authors:  Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2009-06-30       Impact factor: 5.396

6.  Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

Authors:  Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

7.  Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

Authors:  Hong-Tao Xu; Yudong Quan; Eugene Asahchop; Maureen Oliveira; Daniella Moisi; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-10-07       Impact factor: 4.602

8.  HIV Genetic Diversity and Drug Resistance.

Authors:  André F Santos; Marcelo A Soares
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

9.  Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

Authors:  Mark A Wainberg; Bluma G Brenner
Journal:  Viruses       Date:  2010-11-11       Impact factor: 5.048

10.  The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.

Authors:  Mark A Wainberg; Bluma G Brenner
Journal:  Mol Biol Int       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.